Arsenic Agent Shuts Down 2 Hard-To-Treat Cancers In Animal Experiments

Published December 24, 2010

Arsenic Agent Shuts Down 2 Hard-To-Treat Cancers In Animal Experiments
The drug is already FDA-approved for one kind of cancer. Researchers say immediate clinical applications to treat other cancers is possible Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing’s …
Read more on redOrbit

Novartis Gains FDA Approval for Amturnide(TM), a Triple-Combination Pill to Treat High Blood Pressure in Patients …
EAST HANOVER, N.J., Dec. 22, 2010 /PRNewswire/ — Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the …
Read more on redOrbit

Rash Due to Lung Cancer Drug May Be Linked to Better Survival
MONDAY, Dec. 20 (HealthDay News) — Lung cancer patients who develop a rash after treatment with the drug cetuximab (Erbitux) have better outcomes, according to a new study.
Read more on HealthDay via Yahoo! News